June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Enhancement of AAV2-mediated retinal transduction in diabetic rats
Author Affiliations & Notes
  • Nundehui Díaz-Lezama
    Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
  • Zhijian Wu
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD
  • Mayda Ramírez
    Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
  • Bibiana Moreno-Carranza
    Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
  • Gonzalo Martinez de la Escalera
    Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
  • Peter Colosi
    Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD
  • Carmen Clapp
    Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
  • Footnotes
    Commercial Relationships Nundehui Díaz-Lezama, None; Zhijian Wu, None; Mayda Ramírez, None; Bibiana Moreno-Carranza, None; Gonzalo Martinez de la Escalera, None; Peter Colosi, None; Carmen Clapp, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2716. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nundehui Díaz-Lezama, Zhijian Wu, Mayda Ramírez, Bibiana Moreno-Carranza, Gonzalo Martinez de la Escalera, Peter Colosi, Carmen Clapp; Enhancement of AAV2-mediated retinal transduction in diabetic rats. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2716. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular gene therapy based on the adeno-associated virus (AAV) vector-mediated delivery of antiangiogenic molecules offers considerable promise for the treatment of diabetic retinopathy. AAV type-2 (AAV2) uses cell surface heparan sulphate proteoglycans (HSPG) as the primary receptors for cell entry. HSPGs are present on retinal ganglion cells, and likely mediate vector transduction. Here, we compared the transduction of retinal ganglion cells in diabetic and normal rats following intravitreal delivery of AAV2 vectors, and investigated whether such transduction correlates with the level of HSPG expression in the respective retinas.

Methods: An AAV2 CMV EGFP reporter vector was delivered by intravitreal injection (2.8e10 vg/eye) to adult non-diabetic rats (controls) and diabetic rats treated two weeks prior with a single injection of streptozotocin. One month after vector administration, retinal flatmounts were examined for EGFP expression, by confocal microscopy, and expression of the HSPGs syndecan, glypican, and perlecan, by quantitative PCR.

Results: In normal rat retinas, transduction was limited to occasional cells in the ganglion cell layer. In the diabetic rats, the transduction was enhanced more than 4-fold in ganglion cell somas and processes. The expression of mRNAs for syndecan and glypican was elevated 2- and 1.5-fold in the diabetic rat retina, respectively, whereas that of perlecan was not modified.

Conclusions: Retinal transduction by AAV2 vectors is enhanced in diabetes and may be mediated by elevated expression of HSPGs on ganglion cells. The diabetes-induced factors responsible for these changes warrant further study. AAV2 vectors may be desirable for gene therapeutics targeting in diabetic retinopathy.

Keywords: 498 diabetes • 538 gene transfer/gene therapy • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×